NEW YORK ( TheStreet) -- "Don't take your cues from the idiotic sellers," Jim Cramer told his "Mad Money" TV show viewers on Friday. He said if you believe the press, nothing will ever go right in this world, but nothing could be farther from the truth. Cramer told viewers to forget the averages, which are being forced lower by panic hedge fund selling, and focus instead on companies with great earnings. For next week's game plan, Cramer said he'll be watching shoe giant Nike ( NIKE) on Monday. He said Nike delivered an awful quarter last time around, but positive comments from Finish Line ( FINL) might signal a turnaround. Cramer said Nike is a wait-and-see stock. On Tuesday, Cramer said Shaw Group ( SHAW) will provide a read on the nuclear industry post-Japan, while General Mills ( GIS) will enlighten us on the cost of food and transportation on Wednesday. > >> Bull or Bear? Vote in Our Poll Also on Wednesday, Family Dollar ( FDO) reports. Cramer said he's a fan of this discounter that's remodeling stores and taking share. KB Homes ( KBH) will also provide an outlook on housing on Wednesday and seed giant Monsanto ( MON) also reports. Cramer said he prefers DuPont ( DD) over Monsanto. For Thursday, Cramer said Schnitzer Steel ( SCHN) will have his attention for the latest on Chinese steel imports while his favorite restaurant chain Darden Restaurants ( DRI), purveyors of Red Lobster and Olive Garden, will provide insights on how the consumer is fairing with sub-$4 gasoline. In the IPO market, Cramer said he'd try and get in on the Home Away deal set to debut under the ticker AWAY. Cramer said this website for vacation rental homes should be good for a quick pop.
Bioscience Speculation PlayFor "Speculation Friday," Cramer highlighted Pacific Biosciences ( PACB), which is developing a third-generation DNA sequencing technology for a host of applications. Cramer said Pacific Biosciences is not yet profitable and likely won't be until the end of 2014, however given that the $1.2 billion DNA sequencing business is growing at 20% to 25% annually, the upside for the company is sizable. Cramer explained that when the human genome project first sequenced human DNA, the process took 13 years and cost $13 billion. The same process today costs just $10,000 and that cost is expected to fall to just $2,000 as newer technology, like that of Pacific Biosciences, comes into fruition. Cramer said the beauty of Pacific Bioscience's technology is that it can be used for any DNA, not just human DNA. That means the sequencer can be used for agriculture for genetically modified seeds and a host of other applications outside of just the health care arena. Better still, Pacific Biosciences not only makes money as it sells one of its sequencing machines, the company also makes money selling consumables and service after the sale as well. Cramer said every portfolio should have a little speculation in it, and Pacific Biosciences might offer that bit of excitement your portfolio is looking for.
Big Blue's Ambitious PlansRounding out his series on company's with great five-year plans for growth, Cramer highlighted IBM ( IBM), a stock which he owns for his charitable trust,